Cargando…

Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients

Most patients with multiple myeloma (MM) undergoing autologous hematopoietic stem cell transplantation (autoHCT) eventually relapse, perhaps due to the presence of clonal plasma cells (CPC) in the autograft. We conducted a retrospective analysis to evaluate the impact of CPC in the autograft on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasvolsky, Oren, Milton, Denái R., Rauf, Mikael, Ghanem, Sassine, Masood, Adeel, Mohamedi, Ali H., Tanner, Mark R., Bashir, Qaiser, Srour, Samer, Saini, Neeraj, Lin, Paul, Ramdial, Jeremy, Nieto, Yago, Tang, Guilin, Lee, Hans C., Patel, Krina K., Kebriaei, Partow, Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z., Rezvani, Katy, Champlin, Richard, Shpall, Elizabeth J., Lin, Pei, Qazilbash, Muzaffar H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156676/
https://www.ncbi.nlm.nih.gov/pubmed/37137874
http://dx.doi.org/10.1038/s41408-023-00842-6
_version_ 1785036588805259264
author Pasvolsky, Oren
Milton, Denái R.
Rauf, Mikael
Ghanem, Sassine
Masood, Adeel
Mohamedi, Ali H.
Tanner, Mark R.
Bashir, Qaiser
Srour, Samer
Saini, Neeraj
Lin, Paul
Ramdial, Jeremy
Nieto, Yago
Tang, Guilin
Lee, Hans C.
Patel, Krina K.
Kebriaei, Partow
Thomas, Sheeba K.
Weber, Donna M.
Orlowski, Robert Z.
Rezvani, Katy
Champlin, Richard
Shpall, Elizabeth J.
Lin, Pei
Qazilbash, Muzaffar H.
author_facet Pasvolsky, Oren
Milton, Denái R.
Rauf, Mikael
Ghanem, Sassine
Masood, Adeel
Mohamedi, Ali H.
Tanner, Mark R.
Bashir, Qaiser
Srour, Samer
Saini, Neeraj
Lin, Paul
Ramdial, Jeremy
Nieto, Yago
Tang, Guilin
Lee, Hans C.
Patel, Krina K.
Kebriaei, Partow
Thomas, Sheeba K.
Weber, Donna M.
Orlowski, Robert Z.
Rezvani, Katy
Champlin, Richard
Shpall, Elizabeth J.
Lin, Pei
Qazilbash, Muzaffar H.
author_sort Pasvolsky, Oren
collection PubMed
description Most patients with multiple myeloma (MM) undergoing autologous hematopoietic stem cell transplantation (autoHCT) eventually relapse, perhaps due to the presence of clonal plasma cells (CPC) in the autograft. We conducted a retrospective analysis to evaluate the impact of CPC in the autograft on the outcomes of high-risk chromosomal abnormalities (HRMM) patients undergoing autoHCT between 2008 and 2018. Patients were divided into CPC+ or CPC− in the autograft by next-generation flow cytometry (NGF). There were 75 CPC + autografts (18%) and 341 CPC− (82%). The CPC + group was less likely to achieve MRD-negative complete remission post-transplant (11% vs. 42%; p < 0.001). Median progression free survival (PFS) and overall survival (OS) were (12.8 vs. 32.1 months) and (36.4 vs. 81.2 months) in the CPC + and CPC− groups, respectively (both p < 0.001). Also in the subset of patients with MRD-negative ≥VGPR prior to autoHCT, those with CPC + autografts had inferior PFS (HR 4.21, p = 0.006) and OS (HR 7.04, p = 0.002) compared to CPC-. In multivariable analysis, the degree of CPC positivity in the autograft was independently predictive of worse PFS (HR 1.50, p = 0.001) and OS (HR 1.37, p = 0.001). In conclusion, both the presence and degree of CPC in the autograft were highly predictive of inferior PFS and OS.
format Online
Article
Text
id pubmed-10156676
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-101566762023-05-05 Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients Pasvolsky, Oren Milton, Denái R. Rauf, Mikael Ghanem, Sassine Masood, Adeel Mohamedi, Ali H. Tanner, Mark R. Bashir, Qaiser Srour, Samer Saini, Neeraj Lin, Paul Ramdial, Jeremy Nieto, Yago Tang, Guilin Lee, Hans C. Patel, Krina K. Kebriaei, Partow Thomas, Sheeba K. Weber, Donna M. Orlowski, Robert Z. Rezvani, Katy Champlin, Richard Shpall, Elizabeth J. Lin, Pei Qazilbash, Muzaffar H. Blood Cancer J Article Most patients with multiple myeloma (MM) undergoing autologous hematopoietic stem cell transplantation (autoHCT) eventually relapse, perhaps due to the presence of clonal plasma cells (CPC) in the autograft. We conducted a retrospective analysis to evaluate the impact of CPC in the autograft on the outcomes of high-risk chromosomal abnormalities (HRMM) patients undergoing autoHCT between 2008 and 2018. Patients were divided into CPC+ or CPC− in the autograft by next-generation flow cytometry (NGF). There were 75 CPC + autografts (18%) and 341 CPC− (82%). The CPC + group was less likely to achieve MRD-negative complete remission post-transplant (11% vs. 42%; p < 0.001). Median progression free survival (PFS) and overall survival (OS) were (12.8 vs. 32.1 months) and (36.4 vs. 81.2 months) in the CPC + and CPC− groups, respectively (both p < 0.001). Also in the subset of patients with MRD-negative ≥VGPR prior to autoHCT, those with CPC + autografts had inferior PFS (HR 4.21, p = 0.006) and OS (HR 7.04, p = 0.002) compared to CPC-. In multivariable analysis, the degree of CPC positivity in the autograft was independently predictive of worse PFS (HR 1.50, p = 0.001) and OS (HR 1.37, p = 0.001). In conclusion, both the presence and degree of CPC in the autograft were highly predictive of inferior PFS and OS. Nature Publishing Group UK 2023-05-03 /pmc/articles/PMC10156676/ /pubmed/37137874 http://dx.doi.org/10.1038/s41408-023-00842-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Pasvolsky, Oren
Milton, Denái R.
Rauf, Mikael
Ghanem, Sassine
Masood, Adeel
Mohamedi, Ali H.
Tanner, Mark R.
Bashir, Qaiser
Srour, Samer
Saini, Neeraj
Lin, Paul
Ramdial, Jeremy
Nieto, Yago
Tang, Guilin
Lee, Hans C.
Patel, Krina K.
Kebriaei, Partow
Thomas, Sheeba K.
Weber, Donna M.
Orlowski, Robert Z.
Rezvani, Katy
Champlin, Richard
Shpall, Elizabeth J.
Lin, Pei
Qazilbash, Muzaffar H.
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
title Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
title_full Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
title_fullStr Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
title_full_unstemmed Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
title_short Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
title_sort impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156676/
https://www.ncbi.nlm.nih.gov/pubmed/37137874
http://dx.doi.org/10.1038/s41408-023-00842-6
work_keys_str_mv AT pasvolskyoren impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT miltondenair impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT raufmikael impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT ghanemsassine impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT masoodadeel impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT mohamedialih impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT tannermarkr impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT bashirqaiser impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT sroursamer impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT sainineeraj impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT linpaul impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT ramdialjeremy impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT nietoyago impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT tangguilin impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT leehansc impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT patelkrinak impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT kebriaeipartow impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT thomassheebak impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT weberdonnam impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT orlowskirobertz impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT rezvanikaty impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT champlinrichard impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT shpallelizabethj impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT linpei impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients
AT qazilbashmuzaffarh impactofclonalplasmacellsinautograftsonoutcomesinhighriskmultiplemyelomapatients